Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation
Unit of Bone and Soft Tissue Oncology, Division of Oncology, The Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239, Israel. firstname.lastname@example.org
- Published online on: November 1, 2004 https://doi.org/10.3892/ijmm.14.5.931
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The emerging anti-cancer approach is based on combining a ‘traditional’ cytotoxic drug with a ‘signaling’ blocking agent. Such combination, if designed and applied properly, may increase selectivity towards tumor cells. The use of such combinations requires smart planning and choice of the drugs to be combined, their proper dosing as well as correct sequence and schedule of application. The combination of the anti-metabolite gemcitabine and the mTOR blocker, rapamycin, has achieved an impressive response in a patient with metastatic leiomyosarcoma.